The Bradbury Laboratory is dedicated to understanding disease mechanisms and developing therapeutic approaches for rare, pediatric neurodegenerative disorders. Advances in adeno-associated virus (AAV) vectors have led to safer and more efficient viral vehicles to deliver therapeutic transgenes in a single injection, and gene therapy is now a favorable therapeutic intervention for monogenic diseases. A primary focus of the Bradbury lab is improving AAV targeting of myelinating cells, a current limitation of AAV, in order to advance therapeutic outcomes for leukodystrophies and other white matter disorders. The Bradbury lab is translational in nature with a commitment to safely and efficiently moving therapies into the clinic for rare, pediatric disorders.
About Dr. Bradbury
Allison M. Bradbury, MS, PhD
Allison M. Bradbury, MS, PhD is an assistant professor in the Department of Pediatrics at The Ohio State University and a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute. Dr. Bradbury earned her PhD in Biomedical Sciences from Auburn University with her doctoral research focused on development of adeno-associated virus (AAV) gene therapy for the GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), which is currently in human clinical trials. Her postdoctoral research was performed at the University of Pennsylvania, where she was awarded a NRSA Postdoctoral Research Fellowship. During this time Dr. Bradbury evaluated disease mechanisms and developed gene therapy approaches for globoid cell leukodystrophy, also known as Krabbe disease. She joined the Center for Gene Therapy at Nationwide Children’s Hospital in January 2020.
Doctorate: Auburn University
Date Completed: 05/2014